Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species

20 May 2010

Abstract excerpt

A major challenge in developing vaccines for emerging pathogens is their continued evolution and ability to escape human immunity. Therefore, an important goal of vaccine research is to advance vaccine candidates with sufficient breadth to respond to new outbreaks of previously undetected viruses. Ebolavirus (EBOV) vaccines have demonstrated protection against EBOV infection in nonhuman primates (NHP) and show...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Viral Infections and Outbreaks Research
Share to Viral Infections and Vectors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20502688
DOI: 10.1371/journal.ppat.1000904

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus SpeciesPMID 20502688Read ↗

Single Immunization With a Monovalent Vesicular Stomatitis Virus–Based Vaccine Protects Nonhuman Primates Against Heterologous Challenge With Bundibugyo ebolavirusSemantic proximity Read ↗

VSV-based vaccine provides species-specific protection against Sudan virus challenge in macaquesSemantic proximity Read ↗

Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirusSemantic proximity Read ↗

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsSemantic proximity Read ↗

The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigsSemantic proximity Read ↗

Induction of Broad Cytotoxic T Cells by Protective DNA Vaccination Against Marburg and EbolaSemantic proximity Read ↗

Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 ProteinsSemantic proximity Read ↗

Homologous and Heterologous Protection of Nonhuman Primates by Ebola and Sudan Virus-Like ParticlesSemantic proximity Read ↗

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Zaire ebolavirus, Sudan ebolavirus, Marburg and Lassa virusesSemantic proximity Read ↗

A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans.Semantic proximity Read ↗

A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challengeSemantic proximity Read ↗

Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.